Inozyme Q4 2022 Earnings Report
Key Takeaways
Inozyme Pharma reported its full year 2022 financial results, highlighting upcoming clinical and regulatory milestones remaining on track with previous guidance, and current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024.
Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO.
Matthew Winton, Ph.D., appointed COO.
Upcoming clinical and regulatory milestones remain on track with previous guidance.
Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirement into the fourth quarter of 2024.
Inozyme
Inozyme
Forward Guidance
Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of December 31, 2022, together with the additional $20.0 million borrowed on February 15, 2023 under its existing debt facility, will enable the Company to fund cash flow requirements into the fourth quarter of 2024.